Author

A. E. Powell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Bioengineering· 4 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:drug response / drug discovery· 5 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Organism:mouse· 3 Assay:proteomics· 3 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

P. S. Kim· 4 shared B. S. Ou· 3 shared E. Appel· 3 shared E. C. Gale· 3 shared J. Yan· 3 shared G. A. Roth· 2 shared M. Sanyal· 2 shared V. C. T. M. Picece· 2 shared

Activity by Year

2019-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

P. S. Kim

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Design of universal Ebola virus vaccine candidates via immunofocusing

D. Xu, A. E. Powell, A. Utz, M. Sanyal, J. Do, J. J. Patten, J. I. Moliva, N. J. Sullivan, R. A. Davey, P. S. Kim

This paper designs universal Ebola virus vaccine candidates using hyperglycosylation to focus antibody responses on conserved epitopes, showing cross-neutralizing activity against multiple orthoebolavirus species.

bioRxiv · Oct 14, 2023 · PreprintImmunology

Nanoparticle-Conjugated TLR9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines

B. S. Ou, J. Baillet, V. C. T. M. Picece, E. C. Gale, A. E. Powell, O. M. Saouaf, J. Yan, A. Nejatfard, H. Lopez Hernandez, E. Appel

This paper develops CpG nanoparticle adjuvants that enhance the potency, durability, and breadth of COVID-19 vaccines by improving antigen delivery and immune response.

bioRxiv · Jan 2, 2023 · PreprintBioengineering

Subcutaneous delivery of an antibody against SARS-CoV-2 from a supramolecular hydrogel depot

C. M. Kasse, A. C. Yu, A. E. Powell, G. A. Roth, C. S. Liong, C. K. Jons, A. Buahin, C. L. Maikawa, S. Youssef, J. E. Glanville, E. A. Appel

This paper develops a supramolecular hydrogel depot for subcutaneous delivery of SARS-CoV-2 bnAbs, showing prolonged release and improved pharmacokinetics compared to standard administration.

bioRxiv · May 24, 2022Bioengineering

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

E. Cameroni, C. Saliba, J. E. Bowen, L. E. Rosen, K. Culap, D. Pinto, L. A. VanBlargan, A. De Marco, S. K. Zepeda, J. di Iulio, F. Zatta, H. Kaiser, J. Noack, N. Farhat, N. Czudnochowski, , P

This study shows that Omicron variant's spike protein has enhanced ACE2 binding and reduces neutralizing activity, but some broadly neutralizing antibodies remain effective.

bioRxiv · Dec 12, 2021Immunology

A cGAMP-containing hydrogel for prolonged SARS-CoV-2 RBD subunit vaccine exposure induces a broad and potent humoral response

V. Böhnert, E. C. Gale, L. J. Lahey, J. Yan, A. E. Powell, B. S. Ou, J. A. Carozza, L. Li, E. Appel

A cGAMP-containing hydrogel vaccine enhances RBD subunit vaccine efficacy by enabling sustained antigen and adjuvant delivery, resulting in broader and more potent antibody responses.

bioRxiv · Jul 3, 2021 · PreprintBioengineering

An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory

O. Haabeth, J. Lohmeyer, A. Sallets, T. Blake, I. Sagiv-Barfi, D. Czerwinski, B. McCarthy, A. E. Powell, P. A. Wender, R. M. Waymouth, R. Levy

This paper develops an mRNA SARS-CoV-2 vaccine using CARTs with a TLR-9 agonist, showing it induces neutralizing antibodies and T cell memory in mice.

bioRxiv · Apr 14, 2021Immunology

Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2

E. C. Gale, A. E. Powell, G. A. Roth, E. L. Meany, J. Yan, B. S. Ou, A. K. Grosskopf, J. Adamska, V. C. T. M. Picece, A. I. d'Aquino, B. Pulendran, P. S. Kim, E. Appel

This study shows that slow release of an RBD subunit vaccine via hydrogel enhances neutralizing antibody responses against SARS-CoV-2 compared to bolus administration.

bioRxiv · Mar 31, 2021Bioengineering

Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library

B. N. Bell, A. E. Powell, C. Rodriguez, J. R. Cochran, P. S. Kim

The paper isolates and characterizes three novel neutralizing antibodies against SARS-CoV-2 RBD from a naive human antibody library, showing they neutralize the virus in vitro.

bioRxiv · Jan 7, 2021Immunology

A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice

A. E. Powell, K. Zhang, M. Sanyal, S. Tang, P. A. Weidenbacher, S. Li, T. D. Pham, J. E. Pak, W. Chiu, P. S. Kim

This study shows that a single dose of spike-functionalized ferritin vaccines in mice generates neutralizing antibodies against SARS-CoV-2, with S{Delta}C-Fer showing higher efficacy than other spike formats.

bioRxiv · Aug 28, 2020Immunology

Release of human TFIIB from actively transcribing complexes is triggered upon synthesis of 7 nt and 9 nt RNAs

E. Ly, A. E. Powell, J. Goodrich, J. Kugel

The paper investigates TFIIB release during transcription using a single molecule fluorescence system and finds it occurs at two points with similar kinetics, supporting its role in maintaining Pol II activity during transition to elongation.

bioRxiv · Dec 19, 2019Biochemistry